Low-dose interferon-alpha 2b combined with hydroxyurea versus hydroxyurea alone for chronic myelogenous leukemia

Bone Marrow Transplantation

Volumn 17, Issue SUPPL. 3, 1996, Pages

  Louwagie, A ^a   Delannoy, A ^a   Kluin Nelemans, J C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CML; Cytogenetics; IFN ; Randomized trial; Therapy

Indexed keywords

ANTILEUKEMIC AGENT; HYDROXYUREA; RECOMBINANT ALPHA2B INTERFERON;

ADULT; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFICACY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG TOLERANCE; FEMALE; HUMANS; HYDROXYUREA; INTERFERON ALFA-2B; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED;

EID: 0030014886     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (0)